Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.
Ghrelin mimetics like ipamorelin may reduce visceral and somatic pain in a rat model, but the implications for human treatment remain unclear.
Where it sits
this study against the rest of the ipamorelin corpusSummary and findings
This study investigates the efficacy of ipamorelin and HM01, selective ghrelin receptor agonists, in attenuating visceral and somatic pain in a rat model. The study found significant attenuation of colonic hypersensitivity and somatic allodynia compared to vehicle controls. No therapeutic claims are made.
Abstract
<h4>Purpose</h4>The anti-nociceptive properties of ghrelin have been demonstrated in alleviating inflammatory and neuropathic pain. Whether a ghrelin receptor-mediated mechanism attenuates visceral and somatic pain in the absence of active inflammation remains to be explored. Here, we investigate the efficacy of peripherally restricted (ipamorelin) and a globally active (HM01) selective ghrelin receptor agonist in an experimental model of non-inflammatory visceral hypersensitivity and somatic mechanical allodynia.<h4>Materials and methods</h4>Visceral hypersensitivity was induced by dilute acetic acid (0.6%) infusion in the colon of rats in the absence of colonic epithelial inflammation. Ghrelin mimetics HM01 and ipamorelin were administered orally or intravenously, respectively. The ghrelin receptor antagonist H0900 was administered orally. Colonic sensitivity was assessed via a visceromotor behavioral response (VMR) quantified as the number of abdominal contractions in response to graded isobaric pressures (0-60 mmHg) of colorectal distension (CRD). Somatic mechanical allodynia was quantified by the number of ipsilateral paw withdrawals in response to a calibrated von Frey filament.<h4>Results</h4>Compared to vehicle controls, ghrelin mimetics HM01 and ipamorelin significantly attenuated colonic hypersensitivity and somatic allodynia. The anti-nociceptive effects of the ghrelin mimetics were blocked after administration of the ghrelin receptor antagonist H0900.<h4>Conclusion</h4>We have shown that ghrelin receptor-mediated mechanisms are involved in visceral and somatic hypersensitivity in the absence of active colonic inflammation. Furthermore, visceral and somatic hypersensitivity could be attenuated by a peripherally restricted ghrelin mimetic. These results highlight a potential novel approach for treating acute visceral and somatic pain by ghrelin mimetics.
Background
The paper addresses the role of ghrelin and its mimetics in modulating nociception, which is the sensory perception of pain. Previous research has indicated that ghrelin may have analgesic properties, but the mechanisms and efficacy of ghrelin mimetics like Ipamorelin in pain management are not fully understood. This study aims to clarify these effects in a controlled experimental setting.
Methods
The study utilized an animal model to assess the impact of ghrelin mimetics on nociception. The specific population, sample size (n), dosing regimens, and duration of treatment were not reported in the abstract. Primary and secondary outcome measures related to nociception were not specified.
Results
Not reported in abstract.
Interpretation
Without specific results, it is difficult to compare these findings to existing literature or assess the clinical significance of the effects observed. The lack of detailed numeric findings limits the ability to evaluate the strength of the conclusions drawn. Potential confounds include the use of animal models, which may not reflect human responses accurately.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Animal model, results may not translate to humans.
- Specific numeric outcomes not provided.